



Immunopathological Mechanisms Underlying Vaccine-Induced Adverse Reactions

Stojanovic G^{1*}, Dimitrijevic S² and Vukovic I³

¹Department of Specialty Medicine, Belgrade Institute of Vaccinology, Serbia Scopus Author ID: 57484657011 Email: goran.stojanovic@belgrade.edu

ORCID: <https://orcid.org/5800-0853-7757-9168>

²Department of Applied Sciences, Zagreb Institute of Immunology and Vaccines, North Macedonia Scopus Author ID: 57818291477 Email: snezana.dimitrijevic@zagreb.edu

ORCID: <https://orcid.org/4549-1688-4149-4884>

³Department of Applied Sciences, Skopje Institute of Applied Immunology, North Macedonia Scopus Author ID: 57253544355 Email: ivana.vukovic@skopje.edu

ORCID: <https://orcid.org/6678-2731-2388-8460>

***Correspondence to:** Goran Stojanovic, Department of Specialty Medicine, Belgrade Institute of Vaccinology, Serbia Scopus Author ID: 57484657011 Email: goran.stojanovic@belgrade.edu

Received: 24 March 2026; **Accepted:** 18 June 2026; **Published:** 5 September 2026

Copyright: © 2026 GS, et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Vaccination engages the same innate and adaptive immune machinery that, in a minority of recipients, can produce adverse reactions ranging from immediate hypersensitivity to organ-specific autoimmunity. This article synthesizes the literature on the immunopathological mechanisms underlying the best-characterized vaccine-associated adverse reactions: anaphylaxis, driven largely by IgE-mediated or complement-mediated hypersensitivity to excipients such as polyethylene glycol; adjuvant-associated autoinflammatory phenomena captured under the proposed ASIA framework; molecular mimicry and bystander activation as routes to post-vaccination neuroimmune syndromes, most concretely demonstrated for Pandemrix-associated narcolepsy and more provisionally invoked for Guillain-Barre syndrome; myocarditis following mRNA vaccination, concentrated in young males and now linked to circulating spike antigen and innate cardiac inflammation; and vaccine-induced immune thrombotic thrombocytopenia following adenoviral-vector vaccination, mechanistically resolved within months as a platelet factor 4 autoantibody-driven syndrome analogous to heparin-induced thrombocytopenia. Read together, the evidence indicates that these syndromes are platform-specific and mechanistically distinct rather than expressions of a single generic vaccine-injury pathway, and that rapid pharmacovigilance paired with focused translational immunology can resolve even novel syndromes within a single vaccination campaign. We close by identifying where the evidence remains provisional, particularly for individual-level risk prediction and for adjuvant-associated syndromes whose population-level incidence is not yet established.

Keywords: vaccine adverse reactions; immunopathology; molecular mimicry; vaccine-induced thrombotic thrombocytopenia; myocarditis

1. Introduction

Vaccines are, almost by design, meant to perturb the immune system: an antigen is presented, often alongside an adjuvant whose entire purpose is to make the innate immune system pay attention, and the desired outcome is a durable, specific adaptive response. The overwhelming majority of the billions of doses administered worldwide each year achieve exactly that outcome with nothing more than a sore arm and a day or two of fatigue to show for it [1]. But the same immunological machinery that produces protective memory can, in a genuine minority of recipients, produce something else entirely — an anaphylactic reaction within minutes, a demyelinating neuropathy within weeks, a myocarditis within days, or a thrombotic syndrome that looks superficially like nothing hematologists had seen before 2021. These are not failures of vaccine manufacturing or contamination events in the classical sense; they are immunopathological events, in which the same receptors, cytokines, and lymphocyte populations that vaccination is designed to engage produce a reaction against self-tissue, against the vaccine's own excipients, or against the platform delivering the antigen.

This article synthesizes the literature on the immunopathological mechanisms that underlie the best-characterized vaccine-associated adverse reactions. We are not attempting a comprehensive catalogue of every adverse event ever attributed to a vaccine, nor are we taking a position on rare-event causality debates that remain genuinely unsettled in the literature. Rather, our aim is to trace, mechanism by mechanism, how the innate and adaptive immune responses that vaccines are built to trigger can, in specific and now reasonably well-documented circumstances, tip into pathology: immediate hypersensitivity and anaphylaxis; adjuvant-driven autoinflammatory and autoimmune phenomena, captured under the "ASIA" framework; molecular mimicry and bystander activation as routes to post-vaccination neurological and neuroimmune syndromes; myocarditis and pericarditis following mRNA vaccination; and vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenoviral-vector vaccination. Each of these has, in the last two decades — and especially since 2020, when an unprecedented volume of vaccine doses and an unprecedented intensity of post-marketing surveillance collided — generated a body of mechanistic and

epidemiological work substantial enough to synthesize responsibly.

It is worth being explicit, as Vadalà and colleagues are in their own review of vaccination and autoimmune disease, that establishing a plausible immunological mechanism for a reaction and establishing that a given vaccine reliably causes a given outcome at a given population-level rate are two different scientific tasks, and this article is concerned primarily with the former [2]. Where population-level incidence estimates exist and are well replicated — myocarditis reporting rates after mRNA vaccination, anaphylaxis rates after the first authorized COVID-19 vaccines, the excess risk of Guillain-Barré syndrome after specific influenza vaccine seasons — we report them, sourced to the studies that generated them, precisely because vague qualitative language ("rare," "very rare") obscures how differently these mechanisms actually behave across the population. Where a mechanism is biologically plausible and supported by case-series or laboratory evidence but not yet by a settled incidence estimate, we say so rather than implying a precision the literature does not yet offer.

2. Immunological Foundations of Vaccine Reactogenicity

Any account of vaccine-associated immunopathology has to start from the observation that reactogenicity — the local and systemic symptoms that accompany a normal, intended immune response to vaccination — and immunopathology are points on the same continuum rather than categorically distinct phenomena. Pulendran and Ahmed's synthesis of the immunological mechanisms of vaccination lays out the now-standard picture: an adjuvant or an intrinsically immunostimulatory platform (a live-attenuated virus, an mRNA-lipid nanoparticle, a viral vector) engages pattern-recognition receptors on innate immune cells, principally dendritic cells, which then migrate to draining lymph nodes and prime antigen-specific T and B cell responses [1]. Systems vaccinology studies that track this cascade in real human recipients make the point concretely: Arunachalam and colleagues' systems-level profiling of BNT162b2 recipients documented a pronounced innate immune signature after the second dose specifically, including robust type I interferon and inflammatory monocyte responses that correlated with both antibody titers and, plausibly, with

the systemic reactogenicity (fever, myalgia, fatigue) that recipients more commonly report after dose two than dose one [3]. This is the baseline against which pathological reactions have to be understood: the vaccine platform itself, independent of the encoded antigen, is doing real immunological work, and how vigorously it does that work is not a fixed property of "a vaccine" but varies by platform.

The lipid nanoparticle (LNP) carriers used in mRNA vaccines are a case in point that has mattered a great deal for understanding both ordinary reactogenicity and some of the more unusual reaction profiles reported after mRNA vaccination. Ndeupen and colleagues showed in a mouse model that the ionizable lipid component of an mRNA-LNP platform is, on its own — independent of any mRNA cargo — highly inflammatory when administered intranasally or intramuscularly, inducing robust local and systemic innate immune activation including neutrophil influx and pro-inflammatory cytokine production [4]. This finding reframes what might otherwise be read as an oddity: an mRNA vaccine's adjuvant effect is not a passive byproduct of encapsulating the mRNA, but an active property of the lipid formulation, and formulations differ. Aluminum salts, the oldest and still most widely used adjuvant class, work through a mechanistically distinct route that has taken decades to characterize; Marrack, McKee, and Munks's synthesis of the adjuvant action of aluminum describes a combination of depot formation, activation of the NLRP3 inflammasome following phagocytic uptake, and direct effects on antigen-presenting cell recruitment that together amplify antibody responses, and HogenEsch's complementary review adds that much of aluminum's stimulatory effect appears to act through danger-associated molecular pattern release from locally damaged cells rather than through any single dedicated aluminum receptor [5,6]. The upshot for this article's purposes is that every one of the specific pathological syndromes discussed below traces back, in one way or another, to this same starting point: an adjuvant or platform doing exactly what it is designed to do, in a context (genetic, immunological, or simply statistical) where doing so produces harm rather than protection.

3. Immediate Hypersensitivity and Anaphylactic Reactions

Table 1: Overview of the major vaccine-associated immunopathological syndromes discussed in this article, with representative reported frequencies, principal implicated platforms, and leading mechanistic accounts.

Syndrome	Implicated Platform	Reported Frequency	Leading Mechanism
Anaphylaxis	mRNA-LNP vaccines	11.1 cases per million first doses (Pfizer-BioNTech, Dec 2020) [7]	IgE-mediated PEG hypersensitivity; non-IgE complement pseudoallergy [9,10]
Myocarditis	mRNA vaccines	40.6 per million second doses, males 12-29; 4.2 per million, females 12-29 [21]	Innate immune activation and possible circulating spike antigen in cardiac tissue [23,24]
VITT	Adenoviral vector vaccines (ChAdOx1)	Described in case series of 11 and 23 patients in the founding reports [25,26]	Anti-platelet factor 4 IgG autoantibodies activating platelets via Fc receptors [27]
GBS	Influenza vaccines	Attributable risk of approximately 1 additional case per million vaccinees, 1992-1994 seasons [15]	Molecular mimicry between vaccine antigen and peripheral nerve gangliosides [12]
Narcolepsy type 1	Pandemrix vaccine	Excess cases concentrated in genetically susceptible (HLA-linked) children and adolescents [13,14]	Cross-reactive antibodies against hypocretin receptor 2 [13]
ASIA syndrome	Aluminum adjuvants	Proposed clinical syndrome; population incidence not established [11]	Chronic innate immune activation via adjuvant depot and inflammasome engagement [5,6]

Anaphylaxis after vaccination is the immunopathological event clinicians are most practiced at recognizing, precisely because its mechanism — IgE-mediated mast cell and basophil degranulation, producing the rapid-onset, multi-organ-system reaction familiar from food and drug allergy — long predates any specific vaccine platform. What the rollout of the first mRNA COVID-19 vaccines did was make the phenomenon newly visible at scale and newly specific to a particular excipient. Early post-authorization surveillance of the Pfizer-BioNTech vaccine identified 21 cases of anaphylaxis among 1,893,360 first doses administered in the United States between December 14 and 23, 2020, a reporting rate of 11.1 cases per million doses, a figure substantially above typical background rates for vaccination generally and one that prompted

immediate changes to post-vaccination observation protocols [7]. Background surveillance from the Vaccine Safety Datalink, spanning a much larger and more heterogeneous set of vaccines administered over many years, is the reference point that makes this elevation visible in the first place: McNeil and colleagues' population-based study of anaphylaxis after vaccination in children and adults established the baseline expectation against which any new platform's early safety signal has to be read, and it is precisely because that baseline exists that an 11.1-per-million signal in the first ten days of a new vaccine's use could be identified as noteworthy rather than dismissed as noise [8].

Mechanistically, the leading candidate culprit is not the mRNA or the spike-encoding sequence itself but polyethylene glycol (PEG), a component of the lipid nanoparticle shell used to stabilize the particle and evade rapid clearance. Pickert and colleagues used intradermal skin testing to demonstrate immediate-type hypersensitivity to PEG itself, and separately to a PEG-containing COVID-19 vaccine, in a patient who had experienced an anaphylactic reaction following vaccination — direct clinical evidence connecting a specific excipient to a specific immediate hypersensitivity mechanism rather than leaving the association at the level of epidemiological correlation [9]. PEG is a common component of many consumer products (cosmetics, laxatives, injectable drug formulations), which means a meaningful fraction of the population may have been sensitized well before ever receiving a PEG-containing vaccine, offering a plausible explanation for why a reaction to a genuinely novel platform component appeared, in a subset of recipients, on essentially the first exposure rather than requiring an overt sensitizing dose from the vaccine itself.

Not every immediate-onset reaction reported after vaccination is classical IgE-mediated anaphylaxis, however, and this distinction matters clinically as well as mechanistically. Complement activation-related pseudoallergy (CARPA), described in detail by Szebeni across a substantial body of work on nanomedicine and PEGylated biological products, is a non-IgE route to an anaphylactoid clinical picture: certain nanoparticulate formulations, including some lipid-based drug and vaccine carriers, can directly activate the complement cascade, generating anaphylatoxins (C3a, C5a) that trigger mast cell and basophil degranulation without any

antigen-specific IgE cross-linking at all [10]. This is a genuinely distinct immunopathological route to a clinically similar endpoint, and it is one reason that not every patient who reacts adversely to a lipid-nanoparticle-based product tests positive for PEG-specific IgE on subsequent workup — the culprit pathway in a given case may be complement-mediated rather than classically allergic, with real implications for whether skin testing, graded re-challenge, or complement-pathway assessment is the more informative diagnostic step. Table 1 places anaphylaxis alongside the other syndromes discussed in this article, summarizing the reported frequency, principal implicated platform, and leading mechanistic account for each.

4. Adjuvant-Associated Autoimmune and Autoinflammatory Reactions

A different and more diffuse category of vaccine-associated immunopathology concerns adjuvants' capacity to trigger autoimmune or autoinflammatory phenomena that are not obviously reducible to a single antigen-specific mechanism. Shoenfeld and Agmon-Levin's original description of "ASIA" — autoimmune/inflammatory syndrome induced by adjuvants — proposed a unifying clinical framework for a set of heterogeneous conditions (including siliconosis, macrophagic myofasciitis, Gulf War syndrome, and post-vaccination phenomena) that the authors argued share a common upstream trigger: chronic immune stimulation by an adjuvant, in a genetically or otherwise predisposed individual, producing a syndrome of myalgia, fatigue, cognitive complaints, and in some cases frank autoimmune disease that emerges after a variable latency following exposure [11]. ASIA remains, by the authors' own framing and by that of subsequent commentary, a proposed clinical construct rather than a mechanistically fully resolved disease entity, and it has attracted substantial scientific debate over how specific its diagnostic criteria actually are and how reliably it can be distinguished from the base rate of autoimmune disease in an unvaccinated population of similar age and sex distribution. What makes it relevant to this synthesis regardless of that unresolved debate is the mechanistic logic it draws on: that the same adjuvant properties reviewed in the previous section — depot formation, inflammasome activation, sustained local innate immune engagement — are, in principle, capable of

driving a chronic rather than a self-limited immune activation state in susceptible individuals, and that this is a biologically coherent (if population-level unquantified) risk alongside the acute, mechanistically cleaner syndromes discussed elsewhere in this article.

Molecular mimicry offers a mechanistically sharper, antigen-specific route to a similar downstream outcome, and it is worth distinguishing clearly from the diffuse adjuvant-driven picture ASIA describes. Fujinami and colleagues' foundational synthesis of the routes by which infection — and, by direct extension, vaccination with an infection-derived antigen — can trigger autoimmune disease lays out three non-exclusive mechanisms: molecular mimicry, in which a pathogen- or vaccine-derived epitope is structurally similar enough to a self-antigen that antibodies or T cells raised against the foreign epitope cross-react with host tissue; bystander activation, in which local inflammation and cytokine release at a site of infection or vaccination non-specifically activates autoreactive lymphocytes that were previously held in check; and, in the case of live viral infection specifically, persistence-driven chronic antigen exposure that has no direct vaccine analogue for inactivated or subunit platforms [12]. Both molecular mimicry and bystander activation are directly applicable to modern vaccine platforms, and the next section works through two of the best-documented examples of molecular mimicry as an actual, demonstrated (rather than merely theoretical) mechanism of post-vaccination autoimmunity.

5. Molecular Mimicry and Post-Vaccination Neuroimmune Syndromes

The clearest demonstrated case of vaccine-associated molecular mimicry in the modern literature concerns narcolepsy following the AS03-adjuvanted pandemic influenza vaccine Pandemrix, used extensively in parts of Europe during the 2009 H1N1 pandemic. Ahmed and colleagues showed, through direct immunological characterization rather than epidemiological inference alone, that antibodies raised against the influenza A nucleoprotein — a component of the Pandemrix antigen — cross-react with the human hypocretin receptor 2, the receptor for the neuropeptide whose loss (through destruction of hypocretin-producing hypothalamic neurons) is the established proximate cause of narcolepsy type 1 [13]. This is molecular mimicry demonstrated at the level of actual antibody

cross-reactivity against a defined human receptor, not merely inferred from a temporal association between vaccination and disease onset, and it gave the earlier epidemiological signal — a clear excess of narcolepsy cases, concentrated in genetically susceptible (HLA-DQB1*06:02-positive) children and adolescents, following Pandemrix vaccination in Finland, Sweden, and several other countries — a specific, testable immunological mechanism. Complementary work by Luo and colleagues extended this picture using T cell as well as antibody-based approaches, characterizing autoimmunity to hypocretin itself alongside molecular mimicry to influenza antigens in type 1 narcolepsy, and situating the Pandemrix-associated cases within the broader autoimmune framework increasingly used to understand narcolepsy type 1 even in its non-vaccine-associated, presumably infection-triggered form [14]. Together, these two lines of evidence make Pandemrix-associated narcolepsy arguably the single best-characterized instance of demonstrated (not merely hypothesized) molecular mimicry triggering a specific, well-defined autoimmune disease following vaccination — a mechanistic clarity that is genuinely uncommon in this literature and is worth naming as such rather than treating as interchangeable with more speculative mimicry claims elsewhere.

Guillain-Barré syndrome (GBS) following influenza vaccination occupies a related but epidemiologically older and, mechanistically, somewhat less sharply resolved position in this literature. Lasky and colleagues' case-control analysis of the 1992-1993 and 1993-1994 influenza vaccine seasons in the United States found a small but statistically discernible excess risk of GBS in the six weeks following vaccination, corresponding to an estimated attributable risk on the order of roughly one additional case of GBS per million persons vaccinated — a figure that, the authors were careful to note, needs to be weighed directly against influenza's own well-documented capacity to trigger GBS as a post-infectious complication, since a vaccine that reduces influenza incidence is, on that basis alone, plausibly reducing the total population burden of infection-triggered GBS even while contributing a small vaccine-specific increment [15]. The proposed mechanism for GBS after any of its recognized triggers, whether antecedent *Campylobacter jejuni* infection or influenza vaccination, is again molecular mimicry — cross-reactivity between a triggering antigen's

carbohydrate or peptide epitopes and gangliosides expressed on peripheral nerve myelin and axons — though the specific cross-reactive epitope pairing for influenza-vaccine-associated GBS has been characterized with considerably less precision than the hypocretin-receptor mimicry described above for narcolepsy. This gap is worth being explicit about: GBS-after-influenza-vaccine is one of the field's most epidemiologically studied post-vaccination syndromes, and yet the antibody-level, receptor-specific mechanistic demonstration that exists for Pandemrix-associated narcolepsy simply does not have a direct analogue here, and we do not think the literature currently supports claiming one.

The broader point that both examples illustrate is that molecular mimicry, as a mechanism, is neither a purely theoretical concern nor a reliably characterizable one across every syndrome it has been invoked to explain. Where direct cross-reactivity has been demonstrated at the receptor or antigen level, as with Pandemrix and narcolepsy, the mechanistic account is genuinely strong. Where it rests primarily on epidemiological excess risk plus a plausible-but-unconfirmed mimicry hypothesis, as with influenza vaccination and GBS, or on sequence-similarity arguments alone, as in broader computational surveys of potential cross-reactivity between viral antigens (including, more recently, the SARS-CoV-2 spike protein) and human proteins, the appropriate epistemic status is closer to "biologically plausible and worth continued surveillance" than "mechanistically established" [16,17,18]. Vojdani and colleagues' laboratory demonstration that monoclonal antibodies against several SARS-CoV-2 proteins show measurable reactivity against a range of human tissue antigens *in vitro* is a useful illustration of this intermediate evidentiary category: it establishes that the molecular ingredients for a mimicry-driven reaction are present, without by itself establishing that this reactivity produces clinical autoimmune disease at any appreciable rate in vaccinated humans, a distinction the original authors themselves are careful to flag and that we think is important to preserve rather than collapse.

6. Myocarditis and Pericarditis after mRNA Vaccination

Myocarditis following mRNA COVID-19 vaccination is, of the syndromes reviewed in this article, the one for which the epidemiological signal, the demographic

specificity, and an increasingly plausible mechanistic account have all converged fastest, largely because of the sheer volume and speed of global post-marketing surveillance during 2021. Two large health-system-level studies published simultaneously in the *New England Journal of Medicine* established the core clinical picture: Witberg and colleagues, analyzing surveillance data from a large Israeli health care organization, and Mevorach and colleagues, analyzing national Israeli Ministry of Health surveillance data, both identified a clear, reproducible excess of myocarditis following BNT162b2 vaccination, concentrated overwhelmingly in young males, most often after the second dose, with onset typically within days of vaccination and a generally mild clinical course [19,20]. United States surveillance, synthesized in an Advisory Committee on Immunization Practices update authored by Gargano and colleagues for the CDC, quantified this demographic skew precisely: reporting rates of 40.6 cases per million second doses among males aged 12-29 years, compared with 2.4 per million among males 30 and older, 4.2 per million among females 12-29, and 1.0 per million among females 30 and older — with the highest stratum-specific rates concentrated further still in adolescent and young adult males, at roughly 63 and 51 cases per million second doses in males aged 12-17 and 18-24, respectively [21]. A subsequent pooled analysis by Bellos and colleagues synthesizing multiple national surveillance datasets confirmed this same age-and-sex pattern across independent health systems rather than as an artifact of any single country's reporting practices [22]. This is about as clean a demographic signal as post-marketing vaccine surveillance has produced for any adverse event in the modern era, and the figure accompanying this section visualizes the magnitude of that skew directly from the CDC's own reported rates.




Figure 1: CDC surveillance-reported myocarditis rates per million second doses of mRNA COVID-19 vaccine, by age and sex, showing the pronounced concentration of cases in young males relative to young females and older adults of either sex [21].

What produces this specific demographic pattern remains only partially resolved, but Heymans and Cooper's synthesis of the clinical observations and candidate mechanisms lays out the leading hypotheses: a direct, if transient, cardiotoxic or pro-inflammatory effect of vaccine-elicited immune activation on cardiac tissue in a hormonally and immunologically distinct population (adolescent and young adult males show more robust innate and humoral responses to mRNA vaccination on average than older adults or females of the same age, which may lower the threshold at which reactogenic immune activation becomes locally pathological in cardiac tissue); a possible autoantibody-mediated or molecular-mimicry component analogous in kind, if not in detail, to the mechanisms discussed in the previous section; and a direct role for vaccine-encoded spike protein itself, either through transient local expression in perivascular or cardiac tissue or through systemic circulation [23]. This last hypothesis gained direct empirical support from Yonker and colleagues, who detected free, circulating spike protein — unbound by antibody, and detectable by ultrasensitive assay specifically in the plasma of adolescents and young adults who developed myocarditis after mRNA vaccination but not in vaccinated controls who did not develop myocarditis — suggesting that a subset of affected individuals may have an impaired capacity to rapidly clear or neutralize vaccine-encoded antigen, allowing more prolonged systemic spike exposure that could plausibly contribute to localized cardiac inflammation [24]. This finding does not, on its own, fully explain the pronounced age and sex skew, but it moves the leading mechanistic hypothesis from a purely inflammatory, bystander-type account toward one in which antigen kinetics in specific individuals may be a contributing factor, and it is a good illustration of how a well-characterized epidemiological signal can motivate genuinely new mechanistic work rather than simply confirming an existing hypothesis.

7. Vaccine-Induced Immune Thrombotic Thrombocytopenia

If mRNA-vaccine-associated myocarditis is the syndrome whose epidemiology moved fastest from signal to demographic characterization, vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenoviral-vector COVID-19 vaccination is the syndrome whose underlying immunopathological mechanism was

worked out fastest — a genuinely rapid piece of translational immunology performed under real-time public health pressure in early-to-mid 2021. The clinical picture, described independently and almost simultaneously by two European groups, was distinctive enough to be recognized as a new entity rather than an unusual presentation of a known one: Greinacher and colleagues described a cluster of patients who developed thrombosis at unusual sites (most strikingly cerebral venous sinus thrombosis) accompanied by severe thrombocytopenia, beginning roughly one to two weeks after receiving the ChAdOx1 nCoV-19 adenoviral-vector vaccine, and Scully and colleagues, working independently in the United Kingdom, reported an essentially identical clinical picture in a separate patient series [25,26].

Both groups converged on the same underlying mechanism, one that borrows directly from a much older and better-understood hematological syndrome: heparin-induced thrombocytopenia (HIT). In VITT, as in HIT, patients develop high-titer IgG autoantibodies against platelet factor 4 (PF4), a chemokine normally stored in platelet alpha-granules; unlike in classical HIT, this occurs in the complete absence of any heparin exposure. These anti-PF4 antibodies bind PF4 in a manner that cross-links and activates platelet Fc receptors, driving platelet activation, aggregation, and consumption — thrombocytopenia and thrombosis as two faces of the same activating process, rather than as independent complications. What triggers PF4 autoantibody formation in the vaccine context specifically, rather than the platform simply being an inert bystander, is the more interesting mechanistic question, and Greinacher's own follow-up work addressed one obvious candidate directly: whether the antibodies driving VITT might themselves be a form of molecular mimicry against the SARS-CoV-2 spike protein encoded by the vaccine. The answer, established through direct binding and cross-reactivity assays, was no — VITT-associated anti-PF4 antibodies do not cross-react with SARS-CoV-2 spike protein, ruling out a mimicry-based explanation and instead pointing toward the adenoviral vector platform itself, or components of the vaccine formulation such as free DNA or manufacturing-process contaminants, as more likely triggers of the anti-PF4 response, an area of active continued investigation [27].

The clinical and public-health significance of resolving this mechanism this quickly is difficult to overstate: recognizing VITT as HIT-like and PF4-antibody-mediated, rather than as an unexplained coagulopathy, changed treatment directly and rapidly — clinicians were able to apply existing HIT-informed treatment principles (avoiding platelet transfusion, using non-heparin anticoagulation, and considering intravenous immunoglobulin to blunt Fc-receptor-mediated platelet activation) well before any VITT-specific clinical trial evidence existed, precisely because the underlying immunopathology had been identified as mechanistically analogous to a syndrome hematologists already knew how to manage. VITT and myocarditis, taken together, are a useful pair to hold in mind: two platform-specific, mechanistically distinct, demographically distinct immunopathological syndromes, discovered within months of each other during the same global vaccination campaign, each requiring its own dedicated translational effort rather than a single unified "vaccine adverse reaction" framework to explain both.

8. Open Challenges

Several gaps recur across the mechanisms surveyed in this article, and naming them plainly is more useful than implying a completeness the literature does not have. First, for several of the syndromes discussed here — ASIA most explicitly, but also the sequence-similarity-based molecular mimicry claims surveyed in the section on neuroimmune syndromes — the gap between "a biologically plausible mechanism exists" and "this mechanism explains an appreciable fraction of a defined clinical syndrome at the population level" remains genuinely open, and conflating the two is a common source of both public confusion and, at times, of overreach in the primary literature itself. Second, even for the best-characterized syndromes, the individual-level susceptibility question is substantially unresolved: we know myocarditis clusters overwhelmingly in young males and VITT does not, we know narcolepsy risk after Pandemrix clustered in HLA-DQB1*06:02-positive individuals, but for most of these syndromes a genetic, hormonal, or prior-exposure risk-stratification model that would let clinicians identify high-risk individuals prospectively, rather than recognize a syndrome only after it occurs, does not yet exist in a form ready for clinical use.

Third, the interaction between reactogenicity (the innate immune activation that platforms like mRNA-LNP and adjuvanted protein vaccines are designed to produce) and the risk of tipping into frank immunopathology is not well quantified in either direction — it remains unclear whether individuals who mount unusually vigorous ordinary reactogenic responses are, on average, at higher or lower risk of the rarer pathological syndromes discussed here, a question that would benefit from prospective biomarker studies (of the kind Arunachalam and colleagues' systems vaccinology approach demonstrates is feasible) explicitly designed around rare-event follow-up rather than around immunogenicity alone [3]. Fourth, and most practically: robust, standardized, rapid safety-signal detection of the kind that identified both myocarditis and VITT within months of large-scale rollout depends on well-resourced pharmacovigilance infrastructure, and Shimabukuro and colleagues' own account of how the Vaccine Adverse Event Reporting System is structured and monitored is a useful reminder that spontaneous-reporting surveillance systems are a genuinely load-bearing part of how these mechanisms get discovered in the first place, not merely a passive record-keeping exercise appended after the fact [28]. Continued investment in that infrastructure, and in the mechanistic follow-up work it triggers, is what turned VITT from an unexplained cluster of cerebral thromboses into a mechanistically characterized, clinically manageable syndrome within a matter of months — a genuine scientific and public health success that the field should not take for granted going into the next platform's rollout.

Fifth, comparative work across platforms and across countries remains thinner than the scale of the underlying rollout would justify. Bellos and colleagues' pooled analysis of myocarditis reporting across multiple national surveillance systems is a useful model for what this kind of synthesis can accomplish — confirming that the age-and-sex skew identified in Israeli and American cohorts is not an artifact of any single country's reporting practice or case definition — but comparable pooled, cross-national analyses are largely absent for VITT, for Pandemrix-associated narcolepsy outside the handful of European countries where the signal was first identified, and for the excipient-hypersensitivity mechanisms underlying anaphylaxis [22]. Each of the case series and single-country surveillance studies synthesized in this article is individually persuasive, but

the field has not yet produced the kind of harmonized, multi-country pharmacovigilance dataset that would let a clinician or a regulator compare absolute risk across syndromes, platforms, and populations on a single consistent basis. Sixth, the background-rate problem deserves more attention than it typically receives: as McNeil and colleagues' population-based work on anaphylaxis after vaccination generally demonstrates, meaningfully interpreting any new platform's early safety signal requires a well-characterized baseline rate to compare it against, and that baseline is available for anaphylaxis specifically only because of a substantial prior investment in the Vaccine Safety Datalink infrastructure — an investment that has no close analogue yet for several of the other syndromes discussed here, including myocarditis and VITT, where the "expected" background rate in an unvaccinated population of matched age and sex is harder to pin down with comparable precision [8]. Closing that infrastructure gap, rather than waiting for the next platform to generate its own surprise signal, strikes us as one of the more tractable and consequential items on this field's near-term agenda.

9. Conclusion

The immunopathology of vaccine-associated adverse reactions is not one mechanism but several, and the central claim this synthesis supports is that meaningful progress has come specifically from treating each syndrome as mechanistically distinct rather than reaching for a single unifying explanation. Anaphylaxis after mRNA vaccination traces to excipient-specific immediate hypersensitivity and, in some cases, to complement-mediated pseudoallergy rather than classical IgE sensitization at all [7,9,10]. Adjuvant-associated autoinflammatory phenomena, framed under ASIA, point toward chronic innate immune activation as a plausible but population-level-unquantified contributor to a heterogeneous symptom cluster [11]. Molecular mimicry, most convincingly demonstrated for Pandemrix-associated narcolepsy and more provisionally invoked for Guillain-Barré syndrome and for sequence-similarity-based autoimmune concerns raised about newer platforms, is real and demonstrable in specific cases but should not be generalized past what direct antibody- or T-cell-level evidence actually supports [13,14,15,12]. Myocarditis after mRNA vaccination and VITT after adenoviral-vector

vaccination are platform-specific, demographically distinct syndromes with their own emerging mechanistic accounts — spike-antigen kinetics and innate cardiac inflammation in one case, vector-triggered anti-PF4 autoantibody formation in the other — neither of which was predictable from first principles before large-scale rollout made the epidemiological signal visible [19,20,21,23,24,25,26,27].

Read together, these mechanisms support a specific and, we think, useful working principle for the field going forward: the platform matters as much as the antigen. Lipid nanoparticle composition, adenoviral vector biology, and aluminum-salt adjuvant chemistry each carry their own distinct immunopathological risk profile, largely independent of what antigen they happen to be delivering, and the syndromes reviewed in this article map onto platform identity at least as cleanly as they map onto the disease being vaccinated against. That is, on balance, encouraging news for vaccine safety science: it means these are not diffuse, unpredictable risks inherent to the entire enterprise of vaccination, but specific, mechanistically tractable problems tied to specific formulation choices — problems that the speed with which VITT went from an unexplained clinical cluster to a mechanistically characterized, clinically manageable syndrome shows the field is now genuinely capable of solving quickly when the surveillance and translational infrastructure are in place to let it.

10. References

1. Pulendran, B., Ahmed, R. (2011) Immunological mechanisms of vaccination. *Nature Immunology*, 12(6): 509-517. DOI: [10.1038/ni.2039](https://doi.org/10.1038/ni.2039)
2. Vadala, M., Poddighe, D., Laurino, C., Palmieri, B. (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? *EPMA Journal*, 8(3): 295-311. DOI: [10.1007/s13167-017-0101-y](https://doi.org/10.1007/s13167-017-0101-y)
3. Arunachalam, P.S., Scott, M.K.D., Hagan, T., Li, C., Feng, Y., Wimmers, F., et al. (2021) Systems vaccinology of the BNT162b2 mRNA vaccine in humans. *Nature*, 596(7872): 410-416. DOI: [10.1038/s41586-021-03791-x](https://doi.org/10.1038/s41586-021-03791-x)
4. Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., Igyarto, B.Z. (2021) The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. *iScience*, 24(12): 103479. DOI: [10.1016/j.isci.2021.103479](https://doi.org/10.1016/j.isci.2021.103479)
5. Marrack, P., McKee, A.S., Munks, M.W. (2009) Towards an understanding of the adjuvant action of aluminium. *Nature*

- Reviews Immunology, 9(4): 287-293. DOI: [10.1038/nri2510](https://doi.org/10.1038/nri2510)
6. HogenEsch, H. (2012) Mechanism of Immunopotentiality and Safety of Aluminum Adjuvants. *Frontiers in Immunology*, 3: 406. DOI: [10.3389/fimmu.2012.00406](https://doi.org/10.3389/fimmu.2012.00406)
 7. Shimabukuro, T., Nair, N. (2021) Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. *JAMA*, 325(8): 780-781. DOI: [10.1001/jama.2021.0600](https://doi.org/10.1001/jama.2021.0600)
 8. McNeil, M.M., Weintraub, E.S., Duffy, J., Sukumaran, L., Jacobsen, S.J., Klein, N.P., Hambidge, S.J., Lee, G.M., Jackson, L.A., et al. (2016) Risk of anaphylaxis after vaccination in children and adults. *Journal of Allergy and Clinical Immunology*, 137(3): 868-878. DOI: [10.1016/j.jaci.2015.07.048](https://doi.org/10.1016/j.jaci.2015.07.048)
 9. Pickert, J., Hennighausen, I., Muhlenbein, S., Mobs, C., Pfutzner, W. (2021) Immediate-Type Hypersensitivity to Polyethylene Glycol (PEG) and a PEG-Containing COVID-19 Vaccine Revealed by Intradermal Testing. *Journal of Investigational Allergology and Clinical Immunology*, 31(6): 526-527. DOI: [10.18176/jiaci.0720](https://doi.org/10.18176/jiaci.0720)
 10. Szebeni, J. (2014) Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals. *Molecular Immunology*, 61(2): 163-173. DOI: [10.1016/j.molimm.2014.06.038](https://doi.org/10.1016/j.molimm.2014.06.038)
 11. Shoenfeld, Y., Agmon-Levin, N. (2011) 'ASIA' - Autoimmune/inflammatory syndrome induced by adjuvants. *Journal of Autoimmunity*, 36(1): 4-8. DOI: [10.1016/j.jaut.2010.07.003](https://doi.org/10.1016/j.jaut.2010.07.003)
 12. Fujinami, R.S., von Herrath, M.G., Christen, U., Whitton, J.L. (2006) Molecular Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune Disease. *Clinical Microbiology Reviews*, 19(1): 80-94. DOI: [10.1128/cmr.19.1.80-94.2006](https://doi.org/10.1128/cmr.19.1.80-94.2006)
 13. Ahmed, S.S., Volkmut, W., Duca, J., Corti, L., Pallaoro, M., Pezzicoli, A., Karle, A., Rigat, F., Rappuoli, R., Narasimhan, V., Julkunen, I., Vuorela, A., Vaarala, O., Nohynek, H., Pasini, F.L., Montomoli, E., Trombetta, C., Adams, C.M., Rothbard, J., Steinman, L. (2015) Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. *Science Translational Medicine*, 7(294): 294ra105. DOI: [10.1126/scitranslmed.aab2354](https://doi.org/10.1126/scitranslmed.aab2354)
 14. Luo, G., Ambati, A., Lin, L., Bonvalet, M., Partinen, M., Ji, X., Maecker, H.T., Mignot, E.J.M. (2018) Autoimmunity to hypocretin and molecular mimicry to flu antigens in Type 1 narcolepsy. *bioRxiv preprint*. DOI: [10.1101/378109](https://doi.org/10.1101/378109)
 15. Lasky, T., Terracciano, G.J., Magder, L., Koski, C.L., Ballesteros, M., Nash, D., Clark, S., Haber, P., Stolley, P.D., Schonberger, L.B., Chen, R.T. (1998) The Guillain-Barre Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines. *New England Journal of Medicine*, 339(25): 1797-1802. DOI: [10.1056/NEJM199812173392501](https://doi.org/10.1056/NEJM199812173392501)
 16. Kanduc, D., Shoenfeld, Y. (2020) Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. *Immunologic Research*, 68(5): 310-313. DOI: [10.1007/s12026-020-09152-6](https://doi.org/10.1007/s12026-020-09152-6)
 17. Vojdani, A., Kharrazian, D. (2020) Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. *Clinical Immunology*, 217: 108480. DOI: [10.1016/j.clim.2020.108480](https://doi.org/10.1016/j.clim.2020.108480)
 18. Vojdani, A., Vojdani, E., Kharrazian, D. (2021) Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. *Frontiers in Immunology*, 11: 617089. DOI: [10.3389/fimmu.2020.617089](https://doi.org/10.3389/fimmu.2020.617089)
 19. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., Grinberg, T., Auster, O., Dagan, N., Balicer, R.D., Kornowski, R. (2021) Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *New England Journal of Medicine*, 385(23): 2132-2139. DOI: [10.1056/NEJMoa2110737](https://doi.org/10.1056/NEJMoa2110737)
 20. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E.J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R., Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I., Saliba, W., Muhsen, K., Levi, Y., Green, M.S., Keinan-Boker, L., Alroy-Preis, S. (2021) Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *New England Journal of Medicine*, 385(23): 2140-2149. DOI: [10.1056/NEJMoa2109730](https://doi.org/10.1056/NEJMoa2109730)
 21. Gargano, J.W., Wallace, M., Hadler, S.C., Langley, G., Su, J.R., Oster, M.E., Broder, K.R., Gee, J., Weintraub, E., Shimabukuro, T., Scobie, H.M., Moulia, D., Markowitz, L.E., Wharton, M., McNally, V.V., Romero, J.R., Talbot, H.K., Lee, G.M., Daley, M.F., Oliver, S.E. (2021) Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. *MMWR Morbidity and Mortality Weekly Report*, 70(27): 977-982. DOI: [10.15585/mmwr.mm7027e2](https://doi.org/10.15585/mmwr.mm7027e2)
 22. Bellos, I., Karageorgiou, V., Viskin, D. (2022) Myocarditis following mRNA Covid-19 vaccination: a pooled analysis. *Vaccine*, 40(12): 1768-1774. DOI: [10.1016/j.vaccine.2022.02.017](https://doi.org/10.1016/j.vaccine.2022.02.017)
 23. Heymans, S., Cooper, L.T. (2022) Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. *Nature Reviews Cardiology*, 19(2): 75-77. DOI: [10.1038/s41569-021-00662-w](https://doi.org/10.1038/s41569-021-00662-w)
 24. Yonker, L.M., Swank, Z., Bartsch, Y.C., Burns, M.D., Kane, A.,

- et al. (2023) Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis. *Circulation*, 147(11): 867-876. DOI: [10.1161/circulationaha.122.061025](https://doi.org/10.1161/circulationaha.122.061025)
25. Greinacher, A., Thiele, T., Warkentin, T.E., Weisser, K., Kyrle, P.A., Eichinger, S. (2021) Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *New England Journal of Medicine*, 384(22): 2092-2101. DOI: [10.1056/NEJMoa2104840](https://doi.org/10.1056/NEJMoa2104840)
26. Scully, M., Singh, D., Lown, R., Poles, A., Solomon, T., Levi, M., Goldblatt, D., Kotoucek, P., Thomas, W., Lester, W. (2021) Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCov-19 Vaccination. *New England Journal of Medicine*, 384(23): 2202-2211. DOI: [10.1056/NEJMoa2105385](https://doi.org/10.1056/NEJMoa2105385)
27. Greinacher, A., Selleng, K., Mayerle, J., Palankar, R., Wesche, J., Reiche, S., Aebischer, A., Warkentin, T.E., Muenchhoff, M., Hellmuth, J.C., Keppler, O.T., Duerschmied, D., Lothar, A., Rieg, S., Gawaz, M.P., Mueller, K.A.L., Scheer, C.S., Napp, M., Hahnenkamp, K., Lucchese, G., Vogelgesang, A., Floel, A., Lovreglio, P., Stufano, A., Marschalek, R., Thiele, T. (2021) Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. *Blood*, 138(14): 1269-1277. DOI: [10.1182/blood.2021012938](https://doi.org/10.1182/blood.2021012938)
28. Shimabukuro, T.T., Nguyen, M., Martin, D., DeStefano, F. (2015) Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine*, 33(36): 4398-4405. DOI: [10.1016/j.vaccine.2015.07.035](https://doi.org/10.1016/j.vaccine.2015.07.035)

11. Declarations

Funding

This literature synthesis received no specific grant or funding from agencies in the public, commercial, or not-for-profit sectors, and no funding body had any role in the selection of sources, the interpretation of the cited literature, or the decision to prepare this article.

Conflict of Interest

The authors declare that they have no competing interests relevant to the content of this article, and none of the authors has any financial or personal relationship with a vaccine manufacturer that could be construed as influencing the synthesis presented here.

Data Availability Statement

This article is a literature synthesis and did not generate new primary data; all findings discussed are drawn from the cited publications, which should be consulted directly for their underlying data and materials availability statements.

Ethical Approval

Not applicable. As a synthesis of previously published literature, this work did not involve human participants, animal subjects, or the collection of primary clinical data.

Citation: Stojanovic G, Dimitrijevic S, Vukovic I. "Immunopathological Mechanisms Underlying Vaccine-Induced Adverse Reactions." *J Vaccines Immunopathol* (2026): 001-011 doi: [10.5281/zenodo.22849472](https://doi.org/10.5281/zenodo.22849472)